PMV Pharmaceuticals, Inc.
General ticker "PMVP" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $67.5M (TTM average)
PMV Pharmaceuticals, Inc. follows the US Stock Market performance with the rate: 34.9%.
Estimated limits based on current volatility of 1.8%: low 1.25$, high 1.29$
Factors to consider:
- Total employees count: 47 (-25.4%) as of 2024
- Top business risk factors: Limited operating history, Commercialization challenges, Geopolitical risks, Market competition, Regulatory and compliance
- Price in estimated range
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.02$, 2.72$]
- 2025-12-31 to 2026-12-31 estimated range: [1.06$, 2.77$]
Financial Metrics affecting the PMVP estimates:
- Positive: with PPE of -1.3 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -66.38 <= 0.33
- Positive: Inventory ratio change, % of 0 <= 0
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Negative: negative Industry operating cash flow (median)
- Positive: Investing cash flow per share per price, % of 69.06 > -0.66
Short-term PMVP quotes
Long-term PMVP plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $77.04MM | $80.13MM | $85.45MM |
| Operating Income | $-77.04MM | $-80.13MM | $-85.45MM |
| Non-Operating Income | $3.71MM | $11.17MM | $10.64MM |
| R&D Expense | $51.99MM | $55.88MM | $58.53MM |
| Income(Loss) | $-73.33MM | $-68.96MM | $-74.81MM |
| Taxes | $-0.01MM | $0.00MM | $-16.10MM |
| Profit(Loss)* | $-73.32MM | $-68.96MM | $-58.71MM |
| Stockholders Equity | $246.03MM | $225.69MM | $176.08MM |
| Assets | $270.31MM | $252.15MM | $191.29MM |
| Operating Cash Flow | $-63.76MM | $-55.66MM | $-51.28MM |
| Capital expenditure | $7.98MM | $0.96MM | $0.66MM |
| Investing Cash Flow | $-1.37MM | $-50.55MM | $53.35MM |
| Financing Cash Flow | $0.96MM | $35.58MM | $0.31MM |
| Earnings Per Share** | $-1.61 | $-1.44 | $-1.14 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.